Methylprednisolone pulse therapy compared with intravenous dexamethasone for severe COVID-19 patients: a randomized clinical trial
Bibliographic record
Abstract
BACKGROUND: COVID-19, caused by SARS-CoV-2, leads to severe respiratory complications, often requiring intensive care. Corticosteroids have been widely used to manage inflammation in COVID-19 patients, with dexamethasone and methylprednisolone being among the most commonly administered options. However, their relative efficacy remains a subject of debate. This study aimed to compare the effectiveness of dexamethasone and methylprednisolone in hospitalized COVID-19 patients. METHODS: This double-blind, randomized controlled trial was conducted at Imam-Ali Hospital, Karaj, Iran, on 300 hospitalized COVID-19 patients. Patients were randomly assigned to receive either intravenous dexamethasone (8 mg twice daily) or pulse methylprednisolone (500 mg daily for three days), in addition to standard COVID-19 management. The primary outcomes included mortality rate, ICU length of stay, and the need for mechanical ventilation. Secondary outcomes involved blood oxygen saturation (SpO₂) levels. Statistical analyses were performed using SPSS (version 26). RESULTS: The study included 150 patients in each treatment group. The mortality rate was 12.6% in the dexamethasone group and 15.3% in the methylprednisolone group, with no statistically significant difference (RR: 0.82, P = 0.50). The need for mechanical ventilation was observed in 16.6% of patients in the dexamethasone group and 21.3% in the methylprednisolone group, also without a significant difference (RR: 0.78, P = 0.30). However, ICU stay was significantly shorter in the dexamethasone group (9.5 days) compared to the methylprednisolone group (11.3 days) (P < 0.001). No significant differences were noted in SpO₂ levels between the two groups. CONCLUSION: Both dexamethasone and methylprednisolone demonstrated similar efficacy in outcomes such as mortality rate need for mechanical ventilation in hospitalized COVID-19 patients. However, dexamethasone was associated with a significantly shorter ICU stay, suggesting a potential advantage in hospitalization duration. Further research is needed to refine corticosteroid use and explore additional immunomodulatory strategies to improve COVID-19 outcomes.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.012 | 0.162 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.002 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.002 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".